Here we show that the basic helixloop-helix transcription factor Dec2 was selectively expressed in T H 2 cells. CD4 + T cells from Dec2-deficient mice showed defective T H 2 differentiation in vitro and in vivo in an asthma model and in response to challenge with a parasite antigen. Dec2 promoted expression of interleukin 4 (IL-4), IL-5 and IL-13 during early T H 2 differentiation and directly bound to and activated transcription of genes encoding the transcription factors JunB and GATA-3. As GATA-3 induces Dec2 expression, our findings also indicate a feed-forward regulatory circuit during T H 2 differentiation.
A r t i c l e s CD4 + helper T cells are the central regulators of adaptive immunity and allergic diseases. After being activated by antigen-presenting cells, naive CD4 + precursor cells undergo clonal expansion and functional differentiation into cytokine-secreting effector cells. T helper type 1 (T H 1) cells make interferon-γ (IFN-γ) and promote antigen presentation and cellular immunity 1, 2 . T H 2 cells produce interleukin 4 (IL-4), IL-5 and IL-13, which together regulate antiparasite and allergic responses 1, 2 . IL-17-producing T helper cells (T H -17 cells), distinct from T H 1 and T H 2 cells, secret IL-17, IL-17F, IL-22 and IL-21 and mediate tissue inflammation 3, 4 .
The differentiation of effector helper T cells is determined by the cytokine environment, which ultimately directs the expression of lineage-specific transcription factors 1, 2 . During T H 2 cell polarization, IL-4 is essential, as it activates the transcription factor STAT6, which induces the expression of the transcription factor GATA-3 (ref. 5) . Naive CD4 + T cells start to express IL-4 mRNA 24 h after stimulation of the T cell antigen receptor (TCR) and costimulatory receptors; IL-4 mRNA expression increases even further at 48 h after stimulation 6 . The costimulatory receptor ICOS and the cytokine IL-25 are also important for early IL-4 production, as they promote expression of the transcription factors NFATc1 and JunB (A001301) [7] [8] [9] . In addition to IL-4, IL-2 is involved in the initiation of T H 2 differentiation 10, 11 . When stimulated with low concentrations of antigenic peptide, helper T cells produce IL-4, and this IL-4 production is regulated by IL-2-dependent phosphorylation of STAT5 and IL-4-independent early expression of . IL-2 also facilitates early T H 2 differentiation by inducing expression of the IL-4 receptor α-chain in a manner dependent on STAT5 but independent of IL-4 (ref. 12 ).
However, the precise mechanism that controls initial T H 2 lineage commitment is not well understood. Here we show that Dec2 (also called Sharp1, Bhlhb3, Bhlhb2l and Bhlhe41) 13, 14 , a basic helix-loophelix transcription factor linked before to the regulation of circadian rhythm 15 and differentiation of a range of cell types 16, 17 , was selectively expressed in the T H 2 subset among all helper T cell subsets tested. We found that Dec2 promoted expression of GATA-3 and JunB, the latter of which induces expression of IL-4 (refs. 5, 18, 19) and IL-2 (refs. [20] [21] [22] to promote T H 2 differentiation.
RESULTS

Regulation of Dec2 expression in T H 2 cells
In a gene expression microarray (B.S. and Z.L., data not shown, and Z. Li et al., Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, personal communication), expression of Dec2 mRNA was much higher in T H 2 cells than in T H 1 cells (13.5-fold). We thus further assessed the expression of Dec2 mRNA in T H 1, T H 2, T H -17 and inducible regulatory T cell (iT reg cell) subsets as well as naive CD4 + and CD8 + T cells. We cultured CD4 + T cells purified from OT-II TCR-transgenic mice in T H 1-, T H 2-, T H -17-or iT reg -polarizing conditions in vitro. As measured by quantitative real-time RT-PCR, mRNA encoding Dec2 (Bhlhe41 mRNA; called 'Dec2 mRNA' here) had high expression in T H 2 cells but not in the other types of T cells (Fig. 1a) . Dec2 mRNA was also expressed in non-T lineage cells of the immune system, including plasmacytoid dendritic cells and eosinophils (Supplementary Fig. 1) .
To understand the function of Dec2 in T cells, we tested the kinetics of Dec2 induction during T H 2 differentiation. We purified CD4 + CD25 − CD62L hi CD44 lo naive T cells from C57BL/6 (B6) mice by flow cytometry, activated them for 1-4 d with plate-bound antibody to CD3 (anti-CD3) and anti-CD28 in T H 1-or T H 2-polarizing conditions and assessed gene expression daily. Similar to Gata3 mRNA, Dec2 mRNA expression increased with time in developing T H 2 cells but not in T H 1 cells; in contrast, T H 1 cells but not T H 2 cells had abundant expression of Tbx21 mRNA (encoding the transcription factor T-bet; Fig. 1b) . To determine whether Dec2 is expressed in T H 2 cells generated in physiological conditions, we induced experimental asthma in 4get reporter mice (in which Il4 mRNA expression is indicated by expression of green fluorescence protein (GFP)) 23 and purified IL-4-GFP + and GFP − cells by flow cytometry from the CD4 + CD44 hi population among lung-associated lymph node cells. As expected, Dec2 had high expression in IL-4-GFP + T H 2 cells but not in GFP − non-T H 2 cells (Fig. 1c) . Thus, Dec2 is selectively expressed in T H 2 cells generated in vitro and in vivo.
We next sought to determine how Dec2 expression is regulated during helper T cell differentiation. Costimulatory signals, especially those emanating from ICOS, are important for T H 2 differentiation 9,11 . We thus sorted naive CD4 + T cells from B6 mice and activated them for 1 or 2 d with plate-bound anti-CD3 in the presence or absence of anti-CD28 or/and anti-ICOS. On day 1, stimulation with anti-CD3 plus anti-CD28 induced minimal upregulation of Dec2 mRNA expression, but stimulation with anti-CD3 alone did not (Fig. 1d) . The addition of anti-ICOS further enhanced Dec2 expression. On day 2, Dec2 mRNA was much more abundant in cells that received ICOS costimulation (Fig. 1d) . These results indicate an important role for costimulation, particularly by ICOS, in regulation of Dec2 mRNA expression.
IL-25 facilitates the initiation of T H 2 differentiation 7 . Therefore, we also tested the effect of IL-25 on Dec2 mRNA expression. We activated naive CD4 + T cells from B6 mice for 1-3 d with platebound anti-CD3 and anti-CD28 in the presence or absence of IL-25. Dec2 mRNA expression was strongly boosted in response to IL-25 stimulation (Fig. 1e) .
As Dec2 mRNA is selectively expressed in T H 2 cells, we assessed whether Dec2 expression is regulated by GATA-3, which promotes T H 2 differentiation. We activated naive CD4 + T cells from Il4 +/+ or Il4 −/− mice for 36 h with plate-bound anti-CD3 and anti-CD28 and infected the cells with bicistronic retrovirus encoding GATA-3 and GFP or GFP alone. Then, 2 d later, we sorted GFP + cells by flow cytometry and measured the expression of Dec2 and Il4 mRNA by quantitative RT-PCR. In both Il4 +/+ and Il4 −/− cells, overexpression of GATA-3 increased Dec2 mRNA expression (Fig. 1f) . In addition, we determined whether GATA-3 is required for Dec2 expression. We infected established T H 2 cells with loxP-flanked Gata3 alleles (Gata3 fl/fl ) or Gata3 +/+ T H 2 cells with a bicistronic retrovirus encoding Cre recombinase and GFP 24 . We sorted GFP + cells by flow cytometry after transduction and cultured the cells for 1 or 2 weeks in T H 2-polarizing conditions. We then measured the expression of Dec2 and Il13 mRNA. Unlike Il13 mRNA, whose expression quickly decreased after deletion of Gata3, Dec2 mRNA expression remained stable for 1 week after deletion of Gata3 but diminished after 2 weeks (Fig. 1g) . Next we tested the effect of acute ablation of GATA-3 on Dec2 mRNA expression during early T H 2 differentiation. We activated naive CD4 + T cells from Gata3 fl/fl mice in T H 2-polarizing conditions and infected the cells with Cre-expressing or control retrovirus. Deletion of Gata3 at this early stage of T H 2 differentiation did not substantially influence Dec2 mRNA expression, but it did result in much lower Il13 mRNA expression (Fig. 1h) . Together these findings indicate that Dec2 mRNA expression is induced by costimulatory signals and by IL-25. GATA-3 is sufficient to induce Dec2 mRNA expression but is not necessary for the induction or maintenance of Dec2 mRNA expression.
Dec2 in T H 2 differentiation in vitro
To assess the function of Dec2 in T cell differentiation, we generated Dec2-deficient mice. We introduced two loxP sites into the Dec2 locus flanking the promoter region and exons 1-3. We produced germline Dec2-deficient mice by breeding that mouse with a CMV-Cre mouse 
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volume 10 number 12 december 2009 nature immunology A r t i c l e s (expressing Cre recombinase driven by a cytomegalovirus promoter; Supplementary Fig. 2a,b) . We backcrossed Dec2 +/− mice with B6 mice for six to eight generations and then interbred the progeny to generate Dec2 −/− mice. We used Dec2 −/− mice on a B6 background in all experiments unless indicated otherwise. In Dec2 −/− mice, Dec2 mRNA in bone marrow was not detectable by RT-PCR ( Supplementary Fig. 2c ), and Dec2 protein expression was completely absent from splenocytes when tested by immunoblot ( Supplementary Fig. 2d ). The development of lymphoid populations in thymus and spleen seemed grossly normal in Dec2-deficient mice ( Supplementary Fig. 3 ).
To analyze the role of Dec2 in T cell function, we first examined CD4 + T cell activation in response to stimulation with anti-CD3 and anti-CD28. We sorted naive CD4 + T cells by flow cytometry from Dec2-deficient and control mice and activated the cells with various concentrations of plate-bound anti-CD3 in the presence of a fixed amount anti-CD28. We measured IL-2 production by enzymelinked immunosorbent assay (ELISA) on day 2 and incorporation of [ 3 H]thymidine on day 3. Dec2-deficient CD4 + T cells showed less proliferation and IL-2 production than that of wild-type cells (Fig. 2a) .
Next we assessed the function of Dec2 in helper T cell differentiation. We differentiated naive CD4 + T cells from wild-type and Dec2-deficient mice for 4 d in neutral (T H 0), T H 1, T H 2, T H -17 and iT reg conditions. As shown by intracellular staining, we detected no IL-4 + cells in T H 0 or T H 1 conditions. In T H 0 conditions, Dec2 deficiency resulted in fewer IFN-γ-producing cells (Fig. 2b) . We also observed lower percentages of IFN-γ-producing cells in T H 1 conditions (Fig. 2b) . T H -17-polarizing conditions (transforming growth factor-β (TGF-β) plus IL-6) induced a greater percentage of IL-17-producing cells in Dec2-deficient populations than in wild-type populations; the addition of anti-IFN-γ and anti-IL-4 diminished this difference (Fig. 2b) , which suggests that the enhanced T H -17 differentiation of Dec2-deficient T cells may be due to their impaired production of IFN-γ and/or IL-4. In iT reg conditions, Dec2-deficient T cells developed into Foxp3 + cells as efficiently as wild-type cells did (Fig. 2b) . During T H 2 differentiation in the presence of increasing doses of exogenous IL-4, Dec2 deficiency led to much lower percentages of IL-4-producing cells (Fig. 2c) . As measured by ELISA, Dec2-deficient T cells in these experiments secreted less of the T H 2 cytokines IL-4, IL-5 and IL-13 ( Fig. 2d) . High doses of exogenous IL-4 partially restored IL-4 and IL-5 expression but not IL-13 expression in Dec2-deficient cells. In summary, our analysis of Dec2-deficient T cells indicates that Dec2 is needed for maximal IL-2 production and T H 2 differentiation in vitro.
Dec2 promotes T H 2 responses in vivo.
To analyze the function of Dec2 in vivo, we immunized Dec2-deficient and B6 mice subcutaneously with chicken ovalbumin (OVA) protein in complete Freund's adjuvant (CFA). We isolated splenocytes 5 d later and stimulated them ex vivo with OVA protein. Immunization with OVA in CFA elicited a strong inflammatory response, and Dec2-deficient and wild-type cells expressed similar amounts of IFN-γ and IL-17, and neither Dec2-deficient nor wild-type cells expressed detectable amounts of IL-4 (Fig. 3a) . These results indicate that Dec2 is dispensable for T cell activation and for T H 1 and T H -17 differentiation in vivo.
To determine the role of Dec2 in T H 2 responses in vivo, we immunized mice intraperitoneally with OVA and the adjuvant aluminum hydroxide (alum). After restimulation with OVA, T cells from Dec2-deficient mice had significantly lower expression of IL-4, IL-5 and IL-13 and similar expression of IL-17 and IFN-γ compared with that of T cells from wild-type mice (Fig. 3b) . Next we adoptively transferred CD4 + T cells from Dec2-deficient or wild-type mice together with wild-type B cells into mice deficient in recombination-activating gene 1. Recipients of Dec2-deficient T cells produced less IL-4, IL-5 and IL-13 after immunization with OVA and alum (Fig. 3c) , which suggested that the defective T H 2 cytokine expression in Dec2-deficient mice was due to a CD4 + T cell-intrinsic defect.
T H 2 cells have an important role in immunity to parasite infection. To characterize the role of Dec2 in type 2 immunity, we injected Dec2-deficient and wild-type mice intraperitoneally with Schistosoma mansoni eggs, which elicit strong T H 2 responses 25 . In response to restimulation with soluble egg antigen (SEA), splenocytes from Dec2-deficient animals showed defective T H 2 cytokine expression compared with that of those from wild-type mice (Fig. 3d) . In addition, IFN-γ expression was lower in Dec2-deficient cells but IL-17 expression was not.
As T H 2 cells are pathogenic in asthma, we induced experimental allergic asthma in Dec2-deficient and wild-type mice using a standard protocol 26 . Compared with wild-type mice, Dec2-deficient mice had significantly fewer total cells, eosinophils, neutrophils and lymphocytes in bronchoalveolar lavage fluid (Fig. 4a) . Moreover, after ex vivo restimulation with various doses of OVA protein, lungassociated lymph node cells from Dec2-deficient mice produced less IL-4, IL-5 and IL-13 than did cells from wild-type mice (Fig. 4b) .
To rule out the possibility that Dec2 deficiency affects eosinophil development, we injected recombinant mouse IL-5 intraperitoneally into Dec2-deficient and wild-type mice and examined blood eosinophils by Wright-Giemsa staining. We found no substantial difference in the number of blood eosinophils in wild-type and Dec2-deficient mice ( Supplementary Fig. 4) . Thus, the diminished eosinophilia in asthmatic Dec2-deficient mice was probably not due to a defect in eosinophils or IL-5 signaling but instead was caused by less T cell expression of IL-5 in response to challenge with OVA plus alum. In summary, our data indicate that Dec2 is required for T H 2 responses in vivo. (Fig. 5b) . Notably, IL-2 expression was lower in Dec2-deficient cells in T H 0 conditions but in not T H 2 conditions (Fig. 5b) . These results indicate that Dec2 has an important role in early T H 2 differentiation and is required for expression of GATA-3 and JunB.
Dec2 in early T H 2 lineage commitment
To determine if Dec2 is sufficient to initiate T H 2 differentiation, we overexpressed Dec2 by retroviral transduction. We activated naive CD4 + T cells from wild-type mice with plate-bound anti-CD3 and anti-CD28 in the presence or absence of a blocking antibody specific for IFN-γ. Then, 36 h later, we infected the activated cells with bicistronic retrovirus encoding GFP alone or with Dec2. We sorted GFP + cells by flow cytometry 2 d after infection and assessed their gene expression profiles by real-time RT-PCR. In both the presence and absence of anti-IFN-γ, Dec2 overexpression greatly enhanced the expression of Il2, Il4, Il5, Il13, Gata3, Junb, Il4ra and Il17rb mRNA, whereas expression of Ifng (encoding IFN-γ) and Tbx21 was not changed (Fig. 6a) . Thus, Dec2 is sufficient to upregulate T H 2-specific gene expression, even in neutral conditions.
We then sought to determine whether Dec2 can upregulate T H 2-specific gene expression in unfavorable conditions. First we overexpressed Dec2 in cells cultured in T H 1-or T H -17-polarizing conditions or in the presence of a blocking antibody specific for IL-4. In the presence of anti-IL-4, we detected low expression of Il5 and Il13 mRNA after overexpression of Dec2 (data not shown), which correlated with very modestly higher expression of Gata3 and Junb mRNA; we detected no change in the expression of Tbx21 or Ifng (Fig. 6b and data not shown). In T H 1-polarizing conditions, overexpression of Dec2 resulted in only moderately higher JunB expression (Fig. 6b) . In T H -17-polarizing conditions, both Gata3 and Junb mRNA were significantly higher in cells infected with Dec2-encoding retrovirus than in those infected with control retrovirus, but we detected no (Fig. 6c and data not shown) . In summary, Dec2 overexpression drives T H 2 differentiation in neutral conditions but is not sufficient to promote T H 2 differentiation in T H 1-or T H -17-polarizing conditions.
Dec2 binds to and activates Junb and Gata3
Dec2 can promote T H 2 differentiation, which is IL-4 dependent. Expression of Junb and Gata3 was higher after Dec2 overexpression. We thus reasoned that Dec2 may promote T H 2 differentiation by directly regulating the expression of these factors. Using the VISTA program 27,28 , we searched for conserved noncoding sequences (CNSs) throughout the Gata3, Junb and Il5-Il13-Il4 loci by comparing mouse and human sequences (data not shown). To predict Dec2-binding motifs in the promoters and CNSs, we used the PROMO program 29, 30 ; we found a cluster of potential Dec2-binding sites in a Junb CNS approximately 6-7 kilobases upstream of the transcriptional start site (Supplementary Fig. 5 ), as well as some scattered putative Dec2-binding motifs in the Junb and Gata3 promoters and in the T H 2 locus-control region (data not shown). To determine if Dec2 directly binds these sites in vivo, we used a transgenic mouse that expresses a Flag-tagged Dec2 protein from a CD2 minilocus 31 (Supplementary Fig. 6 ). We cultured naive CD4 + T cells from these mice in T H 2-polarizing conditions in vitro. We then crosslinked the cells with paraformaldehyde, sonicated the cells and immunoprecipitated nucleic acids with an antibody specific for the Flag tag or a polyclonal antibody specific for Dec2, and with rat or rabbit immunoglobulin G (control), respectively. We then reversed the crosslinks and analyzed the immunoprecipitated nucleic acids by real-time PCR with primers specific for the predicted Dec2-binding regions. In Il17 exon 2, the negative control, there was no detectable binding of Dec2 (Fig. 7a) . Dec2 strongly bound to the Junb CNS and Gata3 promoter region, but we detected no Dec2 binding in the Junb promoter region or in the T H 2 locuscontrol region (Fig. 7a) . To substantiate the results reported above, we differentiated naive CD4 + T cells from OT-II mice into T H 2 cells in vitro with OT-II peptide and splenic antigen-presenting cells and then repeated the chromatin immunoprecipitation (ChIP) experiments with anti-Dec2 and control antibody. Consistent with the results of the ChIP experiments with Dec2-transgenic mice, we detected binding of Dec2 to the Junb CNS and Gata3 promoter in these OT-II T H 2 cells (Fig. 7b) . This binding seemed to be specific, as we detected no binding of Dec2 to the Junb CNS or the Gata3 promoter in Dec2-deficient T cells (Fig. 7c) . To determine whether Dec2 regulates chromatin modifications in the Junb and Gata3 loci, we activated naive T cells from Dec2-deficient and wild-type mice for 2 d in T H 2-polarizing conditions and assessed the abundance of acetylated histone H3 in the Junb CNS and Gata3 promoter by ChIP. Dec2 deficiency resulted in slightly lower histone H3 acetylation in the Gata3 promoter and Junb CNS regions (Fig. 7d) , which suggested a role for Dec2 in regulating chromatin modifications in the Junb and Gata3 loci.
As Dec2 was originally identified as a transcriptional repressor, we tested the activity of Dec2 on the Gata3 promoter and Junb CNS with a dual-luciferase reporter system. Dec2 overexpression resulted in significantly more Gata3 promoter activity (Fig. 7e) . Moreover, Dec2 enhanced the activity of the Junb promoter, but only in the presence of the Junb CNS (Fig. 7e) . Therefore, Dec2 may directly bind to the Junb CNS and the Gata3 promoter to activate their transcription.
Our results reported above suggested Gata3 and Junb are direct and biologically meaningful downstream targets of Dec2. To confirm that hypothesis, we overexpressed GATA-3 and JunB in Dec2-deficient T cells. We activated naive T cells from Dec2-deficient and wild-type (Fig. 7f) . However, overexpression of GATA-3 only partially restored enhanced T H 2 cytokine mRNA expression in Dec2-deficient cells (Fig. 7g) . Together, our data indicate that Dec2 directly binds to Gata3 and Junb loci and activates their transcription; reciprocally, GATA-3 induces Dec2 expression.
Our results thus suggest a feed-forward regulatory circuit during T H 2 differentiation (Supplementary Fig. 7 ).
DISCUSSION
Effector T cell differentiation is regulated by an environmental cytokine milieu that establishes T cell-intrinsic lineage-specific transcriptional programs. T H 2 differentiation is driven by autocrine IL-4 production. However, the initiation and maintenance of IL-4 expression is not well studied. In the present study, we have shown that the transcription factor Dec2 was selectively expressed by T H 2 cells, that Dec2 promoted expression of JunB and GATA-3, and that Dec2 facilitated autocrine expression of IL-4 and IL-2 and T H 2 differentiation. Our data support the idea of a crucial role for Dec2 in T H 2 cell differentiation in vitro and in vivo.
In response to stimulation with anti-CD3 and anti-CD28, Dec2-deficient naive CD4 + T cells also showed impaired proliferation compared with that of wild-type cells; this defect was consistent with less IL-2 production by Dec2-deficient T cells. Notably, in neutral conditions, Dec2-deficient T cell populations also contained considerably fewer IFN-γ + cells. Lower expression of IL-2 and IFN-γ also probably accounted for the enhanced IL-17 expression by Dec2-deficient T cells cultured with TGF-β and IL-6. However, Dec2-deficient mice did not show any substantial defect in T H -17 differentiation in vivo, and Dec2-deficient mice showed diminished T H 1 responses after S. mansoni egg challenge but not in the OVA-plus-alum or OVA-plus-CFA challenge model. In contrast, both in vitro and in vivo, Dec2 deficiency led to defective production of T H 2 cytokines. Dec2-deficient mice showed impaired T H 2 cytokine expression in response to S. mansoni egg challenge. In an allergic asthma model, Dec2-deficient mice had considerably fewer cells, including eosinophils in bronchoalveolar lavage fluid; this was associated with a defect in T H 2 cytokine production but not in IL-5-mediated eosinophilia.
Our analysis of Dec2 expression provides insight into the mechanisms underpinning T H 2 differentiation. In keeping with the importance of costimulatory signals, especially those emanating from ICOS, in T H 2 cell polarization, Dec2 expression was boosted by simultaneous stimulation of ICOS and the TCR. In addition, IL-25, a cytokine established as being able to promote T H 2 differentiation 7 , also enhanced Dec2 expression.
During T H 2 cell differentiation, Dec2 shared an expression pattern and induction kinetics similar to those of GATA-3, which indicates that they are regulated together. In fact, overexpression GATA-3 greatly enhanced Dec2 mRNA expression independently of IL-4 signaling. However, after deletion of Gata3 in established T H 2 cells, Dec2 expression remained stable for 1 week, although it diminished thereafter. In addition, deletion of Gata3 during the early T H 2 differentiation did not substantially alter Dec2 expression. Thus, GATA-3 may be dispensable for the induction and maintenance of Dec2 expression. When T cells were activated in neutral conditions or in the presence of anti-IFN-γ, overexpression of Dec2 resulted in much higher expression of GATA-3, as well as of IL-4, JunB, IL-4 receptor-α and IL-17 receptor B. However, Dec2 did not upregulate GATA-3 expression when T cells were activated in T H 1-polarizing conditions. Thus, Dec2 may require other factors, such as STAT6, to activate GATA-3 expression. Nonetheless, our results collectively suggest a reciprocal regulation model in which Dec2 and GATA-3 participate in regulating T H 2 development.
High doses of exogenous IL-4 partially restored T H 2 cytokine expression in Dec2-deficient cells in vitro, which suggests that Dec2 may be involved in the regulation of early autocrine IL-4 production. We confirmed that hypothesis with Dec2-deficient T cells. NFATc1 and JunB are important in regulating early IL-4 production 32 . As NFATc1 expression was not altered in Dec2-deficient cells, we focused on GATA-3 and JunB, whose expression was much lower with Dec2 deficiency. In neutral and T H -17-polarizing conditions, but not in T H 1-polarizing conditions, forced expression of Dec2 greatly enhanced Junb and Gata3 mRNA expression. As shown by ChIP assay, a CNS upstream of Junb and the Gata3 promoter were directly bound by Dec2. Dec2 deficiency led to less histone H3 acetylation at the Junb CNS and Gata3 promoter, which indicates involvement of Dec2 in the regulation of chromatin modification at these two loci. Although Dec2 is considered a transcriptional repressor, overexpression of Dec2 resulted in greatly enhanced activity of the Gata3 promoter and Junb CNS. Our data thus indicate that GATA-3 and JunB are direct targets of Dec2. In fact, overexpression of JunB fully restored T H 2 cytokine expression in Dec2-deficient cells. Overexpression of GATA-3 partially restored T H 2 cytokine expression. Our results thus indicate that Dec2 activates JunB expression as well as GATA-3 expression, that GATA-3 further regulates Dec2 expression to reinforce an autoregulatory loop and that, in turn, JunB and GATA-3 together with NFATc1 regulate early production of IL-4 and IL-2, which aid in establishing the genetic program of T H 2 differentiation.
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureimmunology/.
Accession code. UCSD-Nature Signaling Gateway (http://www. signaling-gateway.org): A001301.
